Smart in-situ thermo-responsive and ion activated ophthalmic sol-gel system of fluconazole

Abstract

The objective of the current investigation is the development and characterization of in-situ ophthalmic formulation of fluconazole for sustained release at the eye site for a prolong period of time. Sol-gel fluconazole in-situ formulation was prepared by thermo-responsive pluronic F127, Na+ activated sodium alginate alone and in combination, characterization parameters include FTIR spectroscopy, Visual assessment and clarity test, Gelling ability test, pH testing, drug assay, In-vitro drug release and optimized formulation was evaluated for In-vitro antifungal studies by comparing with marketed formulation of fluconazole. Optimized formulation F8 composed of fluconazole (0.3%w/v), Pluronic F127(1%w/v), sodium alginate (0.5%w/v), sodium chloride (0.9w/v), benzalkonium Chloride (0.01%w/v) and acetate buffer pH 4 up to 100%w/v), showed drug-polymer compatibility as per FTIR, high gelling consistency on contact with simulated physiological conditions, 6.9 pH, drug assay was estimated (99.89±0.78 %) with 100% in-vitro drug released for about 6 hours. The in-vitro antifungal study was found to be 18.87±0.65 mm; 20.76±0.23 mm in comparison to marketed fluconazole conventional gel formulation (15.98±0.98 mm; 18.98±0.76 mm) for Candida albicans and Aspergillus niger pathogenic fungal strains respectively. Prepared in-situ ophthalmic sol-gel formulation of fluconazole could be considered as efficient delivery system to sustained the drug at the target site and effectively eradicating deeply rooted pathogenic fungal stains

Keywords

• Thermos-responsive
• Na+ activated
• sol-gel
• fluconazole
• Candida albicans.

References

1. [1] Awwad S, Mohamed Ahmed AHA, Sharma G, et al. Principles of pharmacology in the eye. Br J Pharmacol. 2017;174(23): 4205-4223. [CrossRef]
2. [2] Queckenberg C, Fuhr U. Influence of posture on pharmacokinetics. Eur J Clin Pharmacol. 2009; 65(2): 109-119.[CrossRef]
3. [3] Ringvold A. Corneal epithelium and UV-protection of the eye. Acta Ophthalmol Scand. 1998; 76(2): 149-153.[CrossRef]
4. [4] Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010; 12(3): 348-360. [CrossRef]
5. [5] Agrahari V, Mandal A, Agrahari V, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016; 6(6): 735-754. [CrossRef]
6. [6] Thomas PA. Current perspectives on ophthalmic mycoses. Clin Microbiol Rev. 2003; 16(4): 730-797. [CrossRef]
7. [7] Teweldemedhin M, Saravanan M, Gebreyesus A, Gebreegziabiher D. Ocular bacterial infections at Quiha Ophthalmic Hospital, Northern Ethiopia: an evaluation according to the risk factors and the antimicrobial susceptibility of bacterial isolates. BMC Infect Dis. 2017; 17(1): 207. [CrossRef]
8. [8] Ansari Z, Miller D, Galor A. Current Thoughts in Fungal Keratitis: Diagnosis and Treatment. Curr Fungal Infect Rep. 2013; 7(3): 209-218. [CrossRef]

9. [9] Klotz SA, Penn CC, Negvesky GJ, Butrus SI. Fungal and parasitic infections of the eye. Clin Microbiol Rev. 2000;13(4): 662-685. [CrossRef]
10. [10] Patra, J.K., Das, G., Fraceto, L.F. et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol.2018; 16: 71. [CrossRef]
11. [11] Gooch N, Molokhia SA, Condie R. Ocular drug delivery for glaucoma management. Pharmaceutics. 2012; 4(1): 197-211. [CrossRef]
12. [12] Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. [CrossRef]
13. [13] Okura NU, Yozgatlıb V, Okurc MU, Yoltaşd A, Siafakab PI. Improving therapeutic efficacy of voriconazole against fungal keratitis: Thermo-sensitive in situ gels as ophthalmic drug carriers. J Drug Deliv Sci Technol. 2019; 49: 323–333. [CrossRef]
14. [14] Maggi L, Friuli V, Chiesa E, et al. Improvement of the Firocoxib Dissolution Performance Using Electrospun Fibers Obtained from Different Polymer/Surfactant Associations. Int J Mol Sci. 2019; 20(12): 3084. [CrossRef]
15. [15] Cidade MT, Ramos DJ, Santos J, Carrelo H, Calero N, Borges JP. Injectable Hydrogels Based on Pluronic/Water Systems Filled with Alginate Microparticles for Biomedical Applications. Materials (Basel).2019; 12(7): 1083. [CrossRef]
16. [16] Wickson B. Particulate Matter: USP Requirements and Particle Identification. 2019.
17. [17] Shastri D, Patel L, Parikh R. Studies on in situ Hydrogel: A Smart Way for Safe and Sustained Ocular Drug Delivery. J Young Pharm. 2010; 2(2): 116-120. [CrossRef]
18. [18] Modi G, Chandrul K, Padia M. Spectrophotometric estimation of Blonanserin in pure drug and pharmaceutical formulation. J. Chem. Pharm. Res. 2011; 3, (3): 670–675.
19. [19] Ahmed, M. M., Fatima, F., & Mohammed, A. B. Olive Oil Based Organogels for Effective Topical Delivery of Fluconazole: In-vitro Antifungal Study. JPRI.2020: 32(25), 29-36. [CrossRef]
20. [20] Davis KE, Joseph SJ, Janssen PH. Effects of growth medium, inoculum size, and incubation time on culturability and isolation of soil bacteria. Appl Environ Microbiol. 2005; 71(2): 826-834. [CrossRef]
21. [21] Irimia T, Dinu-Pîrvu CE, Ghica MV. Chitosan-Based In Situ Gels for Ocular Delivery of Therapeutics: A State-of-the-Art Review. Mar Drugs. 2018; 16(10): 373. [CrossRef]
22. [22] Giuliano E, Paolino D, Fresta M, Cosco D. Mucosal Applications of Poloxamer 407-Based Hydrogels: An Overview. Pharmaceutics. 2018; 10(3): 159. [CrossRef]
23. [23] Liu Y, Liu J, Zhang X, Zhang R, Huang Y, Wu C. In situ gelling gelrite/alginate formulations as vehicles for ophthalmic drug delivery. AAPS PharmSciTech. 2010; 11(2): 610-620. [CrossRef]